AAP
GALT icon

Arax Advisory Partners’s Galectin Therapeutics GALT Stock Holding History

Arax Advisory Partners’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-52
Closed -$220 – 4255
2025
Q3 		$220 Buy
+52
New +$196 ﹤0.01% 3441

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Arax Advisory Partners's GALT Position: Q4 2025 in Review

Arax Advisory Partners sold out of Galectin Therapeutics (GALT) in Q4 2025, closing a stake of 52 shares — an estimated $220 sold.

Arax Advisory Partners first reported a position in GALT in Q3 2025 and held it in 1 quarter. The position peaked at $220 in Q3 2025. 98 funds tracked by Wall St. Rank hold GALT as of Q4 2025.

  • Arax Advisory Partners reported no remaining Galectin Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Arax Advisory Partners sold 52 Galectin Therapeutics shares in Q4 2025, an estimated $220.
  • Arax Advisory Partners first reported a position in Galectin Therapeutics in Q3 2025 and held it in 1 quarter.
  • Arax Advisory Partners's Galectin Therapeutics position peaked at $220 in Q3 2025.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q4 2025.

Based on Arax Advisory Partners's 13F filing for Q4 2025, filed 13 Feb 2026.